InDex Pharmaceuticals to attend the ECCO 2023 congress
February 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen. ECCO is the largest forum for specialists in inflammatory bowel disease globally.InDex Pharmaceuticals will also be present at booth #C3-17 in the exhibition hall at the Bella Center. InDex’s team members will be available on site to provide information about cobitolimod and the ongoing phase III program CONCLUDE, which is evaluating the Toll-like receptor 9 agonist cobitolimod, as